首页 > 最新文献

Drugs under experimental and clinical research最新文献

英文 中文
Effect of Ukrain on the growth and metastasizing of Lewis carcinoma in C57BL/6 mice. Ukrain对C57BL/6小鼠Lewis癌生长和转移的影响。
Y Grinevich, S Shalimov, G Bendyuh, O Zahriychuk, Y Hodysh

We studied the effect of the anticancer drug Ukrain on Lewis carcinoma in C57BL/6 mice. A marked progressive anticancer and antimetastatic effect was observed. On day 33 of tumor development, the tumor growth inhibition and metastases inhibition index were 71.5% and 73.1%, respectively. The antimetastatic effect of the drug manifested as a decrease in both number and volume of lung metastases. This finding demonstrates that treatment with Ukrain in Lewis carcinoma-bearing mice not only prevents the formation of new metastases but also inhibits the growth of existing ones. In addition to possessing anticancer and antimetastatic effects, Ukrain has been demonstrated to affect parameters characterizing the state of the immune system. This effect manifested as an increase in the endocrine function of the thymus (a central organ of the immune system), an increase in serum interferon, adhesion of peritoneal macrophages and formation of antibodies against thymus-dependent antigen by spleen plasma cells. Together with intensification of functional activity of the immune system, Ukrain increased the number of lymphoid cells and monocytes in peripheral blood. In addition to the increase in lymphocytes, the number of large granular lymphocytes also increased, i.e., cells possessing natural cytotoxic activity. The results obtained suggest that the antitumor, and especially the antimetastatic, effect of Ukrain is due to its immune-modulating properties, specifically, activation of antitumor resistance concerned with release of interferon and thymus humoral factors. Natural killer (NK) activity is one part of this resistance. NK cells are able to recognize and eliminate from the circulation cells with the potential to form metastases.

我们研究了抗癌药物乌克兰对C57BL/6小鼠Lewis癌的影响。观察到显著的进行性抗癌和抗转移作用。肿瘤发生第33天,肿瘤生长抑制指数和转移抑制指数分别为71.5%和73.1%。药物的抗转移作用表现为肺转移的数量和体积的减少。这一发现表明,在Lewis癌小鼠中使用Ukrain治疗不仅可以防止新转移瘤的形成,还可以抑制现有转移瘤的生长。除了具有抗癌和抗转移作用外,乌克兰已被证明可以影响表征免疫系统状态的参数。这种作用表现为胸腺(免疫系统的中心器官)内分泌功能的增加,血清干扰素的增加,腹膜巨噬细胞的粘附和脾脏浆细胞对胸腺依赖抗原的抗体的形成。随着免疫系统功能活性的增强,乌克兰外周血淋巴样细胞和单核细胞的数量增加。除了淋巴细胞增加外,大颗粒淋巴细胞的数量也增加,即具有天然细胞毒活性的细胞。结果表明,乌兰的抗肿瘤,特别是抗转移作用是由于其免疫调节特性,特别是激活与干扰素和胸腺体液因子释放有关的抗肿瘤抵抗。自然杀伤(NK)活性是这种抵抗力的一部分。NK细胞能够识别并清除循环中有可能形成转移的细胞。
{"title":"Effect of Ukrain on the growth and metastasizing of Lewis carcinoma in C57BL/6 mice.","authors":"Y Grinevich,&nbsp;S Shalimov,&nbsp;G Bendyuh,&nbsp;O Zahriychuk,&nbsp;Y Hodysh","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We studied the effect of the anticancer drug Ukrain on Lewis carcinoma in C57BL/6 mice. A marked progressive anticancer and antimetastatic effect was observed. On day 33 of tumor development, the tumor growth inhibition and metastases inhibition index were 71.5% and 73.1%, respectively. The antimetastatic effect of the drug manifested as a decrease in both number and volume of lung metastases. This finding demonstrates that treatment with Ukrain in Lewis carcinoma-bearing mice not only prevents the formation of new metastases but also inhibits the growth of existing ones. In addition to possessing anticancer and antimetastatic effects, Ukrain has been demonstrated to affect parameters characterizing the state of the immune system. This effect manifested as an increase in the endocrine function of the thymus (a central organ of the immune system), an increase in serum interferon, adhesion of peritoneal macrophages and formation of antibodies against thymus-dependent antigen by spleen plasma cells. Together with intensification of functional activity of the immune system, Ukrain increased the number of lymphoid cells and monocytes in peripheral blood. In addition to the increase in lymphocytes, the number of large granular lymphocytes also increased, i.e., cells possessing natural cytotoxic activity. The results obtained suggest that the antitumor, and especially the antimetastatic, effect of Ukrain is due to its immune-modulating properties, specifically, activation of antitumor resistance concerned with release of interferon and thymus humoral factors. Natural killer (NK) activity is one part of this resistance. NK cells are able to recognize and eliminate from the circulation cells with the potential to form metastases.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40942206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analgesic efficacy of a lecithin-vehiculated diclofenac epolamine gel in shoulder periarthritis and lateral epicondylitis: a placebo-controlled, multicenter, randomized, double-blind clinical trial. 卵磷脂载药双氯芬酸依泊胺凝胶治疗肩周炎和外侧上髁炎的镇痛效果:一项安慰剂对照、多中心、随机、双盲临床试验
G Spacca, A Cacchio, A Forgács, P Monteforte, G Rovetta

Diclofenac epolamine (2-hydroxyethyl-pyrrolidine) (DHEP) is a diclofenac salt endowed with enhanced cutaneous permeation. To optimize its absorption after topical application, a lecithin-enriched DHEP 1.3% gel has been developed (DHEP lecithin gel) and investigated in patients with shoulder periarthritis and lateral epicondylitis in a placebo-controlled, multicenter double-blind clinical trial. One hundred fifty-eight patients were randomized to a 10-day treatment with DHEP lecithin gel or placebo (5 g t.i.d. applied on the painful area). The efficacy criteria were pain measured by visual analog scale (VAS) while performing a specific standardized movement, intake of rescue medication (paracetamol), and the disabilities of the arm, shoulder and hand (DASH) questionnaire. VAS scores indicated a consistently higher analgesic activity of DHEP lecithin gel. At day 3, pain was reduced by -20.1 +/- 20.2 and -9.9 +/- 12.7 mm in the DHEP lecithin gel- and placebo-treated patients, respectively (p < 0.001); at day 6 of treatment, DHEP lecithin gel induced a pain reduction of -33.2 +/- 26.1 mm, while the reduction achieved with placebo was only -21.2 +/- 18.8 mm (p < 0.001). The mean changes in DASH questionnaire indicated that DHEP lecithin gel was more effective than placebo in improving patient well-being and reducing difficulties in performing the activities most severely impaired by rheumatism, while no difference was observed between the two treatments in consumption of rescue medication. In conclusion, these results indicate that DHEP lecithin gel is a topically effective analgesic product in patients with shoulder periarthritis or lateral epicondylitis and provide further evidence on the use of topical nonsteroidal anti-inflammatory drugs as an optimal approach to the treatment of localized musculoskeletal disorders.

双氯芬酸乙polamine(2-羟乙基吡咯烷)(DHEP)是一种双氯芬酸盐,具有增强皮肤渗透性。为了优化外用后的吸收效果,我们研制了一种富含卵磷脂的脱氢磷1.3%凝胶(脱氢磷卵磷脂凝胶),并通过安慰剂对照、多中心双盲临床试验对肩周炎和外上髁炎患者进行了研究。158名患者随机接受DHEP卵磷脂凝胶或安慰剂治疗10天(每次5克,涂抹在疼痛部位)。疗效评价标准为:采用视觉模拟量表(VAS)测量特定标准化运动时的疼痛程度、对乙酰氨基酚(paracetamol)的服用情况、手臂、肩膀和手的残疾程度(DASH)问卷。VAS评分显示DHEP卵磷脂凝胶具有较高的镇痛活性。在第3天,DHEP卵磷脂凝胶组和安慰剂组的疼痛分别减少了-20.1 +/- 20.2和-9.9 +/- 12.7 mm (p < 0.001);在治疗第6天,DHEP卵磷脂凝胶诱导疼痛减轻-33.2 +/- 26.1 mm,而安慰剂的减少仅为-21.2 +/- 18.8 mm (p < 0.001)。DASH问卷的平均变化表明,DHEP卵磷脂凝胶在改善患者幸福感和减少风湿病最严重损害的活动困难方面比安慰剂更有效,而两种治疗在抢救药物的消耗方面没有差异。综上所述,这些结果表明DHEP卵磷脂凝胶是肩周炎或外上髁炎患者的局部有效镇痛产品,并进一步证明外用非甾体类抗炎药是治疗局部肌肉骨骼疾病的最佳方法。
{"title":"Analgesic efficacy of a lecithin-vehiculated diclofenac epolamine gel in shoulder periarthritis and lateral epicondylitis: a placebo-controlled, multicenter, randomized, double-blind clinical trial.","authors":"G Spacca,&nbsp;A Cacchio,&nbsp;A Forgács,&nbsp;P Monteforte,&nbsp;G Rovetta","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Diclofenac epolamine (2-hydroxyethyl-pyrrolidine) (DHEP) is a diclofenac salt endowed with enhanced cutaneous permeation. To optimize its absorption after topical application, a lecithin-enriched DHEP 1.3% gel has been developed (DHEP lecithin gel) and investigated in patients with shoulder periarthritis and lateral epicondylitis in a placebo-controlled, multicenter double-blind clinical trial. One hundred fifty-eight patients were randomized to a 10-day treatment with DHEP lecithin gel or placebo (5 g t.i.d. applied on the painful area). The efficacy criteria were pain measured by visual analog scale (VAS) while performing a specific standardized movement, intake of rescue medication (paracetamol), and the disabilities of the arm, shoulder and hand (DASH) questionnaire. VAS scores indicated a consistently higher analgesic activity of DHEP lecithin gel. At day 3, pain was reduced by -20.1 +/- 20.2 and -9.9 +/- 12.7 mm in the DHEP lecithin gel- and placebo-treated patients, respectively (p < 0.001); at day 6 of treatment, DHEP lecithin gel induced a pain reduction of -33.2 +/- 26.1 mm, while the reduction achieved with placebo was only -21.2 +/- 18.8 mm (p < 0.001). The mean changes in DASH questionnaire indicated that DHEP lecithin gel was more effective than placebo in improving patient well-being and reducing difficulties in performing the activities most severely impaired by rheumatism, while no difference was observed between the two treatments in consumption of rescue medication. In conclusion, these results indicate that DHEP lecithin gel is a topically effective analgesic product in patients with shoulder periarthritis or lateral epicondylitis and provide further evidence on the use of topical nonsteroidal anti-inflammatory drugs as an optimal approach to the treatment of localized musculoskeletal disorders.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25633701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study. 评价利福昔明、安慰剂和乳果糖降低肝硬化患者苯二氮卓类化合物水平:一项初步研究
I Venturini, A Ferrieri, F Farina, F Cosenza, R Avallone, L Corsi, M Baraldi, M L Zeneroli

Benzodiazepine-like compounds (BZDs), either taken with the diet or synthesized by intestinal bacterial flora, may represent a precipitating factor for hepatic encephalopathy (HE) in cirrhotic patients. We evaluated whether a diet and/or treatment with rifaximin or lactulose can reduce serum concentrations of BZDs in 18 cirrhotic patients without HE. Patients were given a standard diet for 7 days to keep the dietary intake of BZDs constant and were then randomized to a 7-day treatment with rifaximin 1,200 mg/day, lactulose 10-20 g three times daily, or placebo. Blood samples were collected at enrollment, at the end of the diet and drug treatment periods, and 7 days after the drug was stopped (follow-up). Serum concentrations of BZDs were measured by a radioligand binding technique after high-performance liquid chromatography extraction and purification and were expressed as diazepam equivalents (DE). No change in serum BZD concentrations was observed during the diet, while a statistically significant decrease from 105.6 +/- 66.5 to 63.5 +/- 49.5 pmol DE/ml was achieved in rifaximin-treated patients (p < 0.05) but not in patients treated with lactulose or placebo. During the followup, serum BZD concentrations returned to 104.5 +/- 74.0 pmol DE/ml in rifaximin-treated patients (p < 0.05 vs. end-treatment values), while no significant change was observed in the lactulose- and placebo-treated patients. These data indicate that control of bacterial flora with cyclic administration of rifaximin plays a pivotal role in avoiding increased plasma concentrations of BZDs, which represent a precipitating factor for HE inpatients with severe liver disease.

苯二氮卓类化合物(BZDs),无论是与饮食一起服用还是由肠道菌群合成,都可能是肝硬化患者肝性脑病(HE)的一个诱发因素。我们评估了饮食和/或利福昔明或乳果糖治疗是否可以降低18例无HE肝硬化患者的血清BZDs浓度。患者给予标准饮食7天,以保持BZDs的饮食摄入量不变,然后随机分为7天治疗组:利福昔明1200毫克/天,乳果糖10-20克,每日3次,或安慰剂。在入组时、饮食和药物治疗期结束时和停药后7天(随访)采集血样。经高效液相色谱提取纯化后,采用放射配体结合技术测定BZDs的血清浓度,并以地西泮当量(DE)表示。在饮食过程中,血清BZD浓度没有变化,而利福昔明治疗的患者从105.6 +/- 66.5降至63.5 +/- 49.5 pmol DE/ml (p < 0.05),而乳果糖或安慰剂治疗的患者则没有变化。在随访期间,利福昔明组患者血清BZD浓度恢复到104.5 +/- 74.0 pmol DE/ml(与治疗结束值相比p < 0.05),而乳果糖组和安慰剂组患者无显著变化。这些数据表明,通过循环给药利福昔明控制细菌菌群在避免BZDs血浆浓度升高中起关键作用,BZDs是HE住院患者合并严重肝病的一个诱发因素。
{"title":"Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study.","authors":"I Venturini,&nbsp;A Ferrieri,&nbsp;F Farina,&nbsp;F Cosenza,&nbsp;R Avallone,&nbsp;L Corsi,&nbsp;M Baraldi,&nbsp;M L Zeneroli","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Benzodiazepine-like compounds (BZDs), either taken with the diet or synthesized by intestinal bacterial flora, may represent a precipitating factor for hepatic encephalopathy (HE) in cirrhotic patients. We evaluated whether a diet and/or treatment with rifaximin or lactulose can reduce serum concentrations of BZDs in 18 cirrhotic patients without HE. Patients were given a standard diet for 7 days to keep the dietary intake of BZDs constant and were then randomized to a 7-day treatment with rifaximin 1,200 mg/day, lactulose 10-20 g three times daily, or placebo. Blood samples were collected at enrollment, at the end of the diet and drug treatment periods, and 7 days after the drug was stopped (follow-up). Serum concentrations of BZDs were measured by a radioligand binding technique after high-performance liquid chromatography extraction and purification and were expressed as diazepam equivalents (DE). No change in serum BZD concentrations was observed during the diet, while a statistically significant decrease from 105.6 +/- 66.5 to 63.5 +/- 49.5 pmol DE/ml was achieved in rifaximin-treated patients (p < 0.05) but not in patients treated with lactulose or placebo. During the followup, serum BZD concentrations returned to 104.5 +/- 74.0 pmol DE/ml in rifaximin-treated patients (p < 0.05 vs. end-treatment values), while no significant change was observed in the lactulose- and placebo-treated patients. These data indicate that control of bacterial flora with cyclic administration of rifaximin plays a pivotal role in avoiding increased plasma concentrations of BZDs, which represent a precipitating factor for HE inpatients with severe liver disease.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25633705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic effect of D-004, a lipid extract from Roystonea regia fruits, on prostate hyperplasia induced in rats. 皇石果脂质提取物D-004对大鼠前列腺增生的治疗作用。
D Carbajal, V Molina, R Mas, M L Arruzazabala

Benign prostatic hyperplasia (BPH) is a nonmalignant growth of prostate leading to difficulty in urinating. Drug therapy, phytotherapy included, is frequently used to treat BPH. D-004 is a lipid extract from Roystonea regia fruits, and previous studies have shown that oral treatment with D-004 for 14 days prevented prostate hyperplasia (PH) induced by testosterone in rats. No information is available, however; about the effects of D-004 in reverting already established PH. This study investigated whether D-004 could improve PH after oral dosing with testosterone in rats. Rats were distributed in five groups (10 rats/group). One group was injected with soy oil (negative control) and four groups were injected with testosterone: one was orally treated with the vehicle (positive control), two with D-004 (200 and 400 mg/kg) and the other with Saw palmetto (400 mg/kg). At study completion, the rats were sacrificed and the prostates were removed and weighed. D-004 (200 and 400 mg/kg) significantly and dose-dependently decreased prostate enlargement by 85% and 98%, respectively, versus the positive control. Likewise, Saw palmetto (400 mg/kg) significantly reduced prostate weight by 73% versus the positive control. D-004 (400 mg/kg) was more effective (p < 0.05) than Saw palmetto (400 mg/kg) in lowering prostate enlargement. D-004 and Saw palmetto also decreased the prostate weight to body weight ratio, but did not affect body weight. In conclusion, D-004 (200 and 400 mg/kg) orally administered was effective for reducing PH after testosterone dosing. D-004 (400 mg/kg) was more effective than Saw palmetto (400 mg/kg). Further studies, however, are needed to corroborate the present results.

良性前列腺增生(BPH)是一种非恶性前列腺增生,导致排尿困难。药物疗法,包括植物疗法,经常用于治疗前列腺增生。D-004是Roystonea regia水果的脂质提取物,先前的研究表明,口服D-004 14天可以预防睾酮诱导的大鼠前列腺增生(PH)。然而,目前尚无相关信息;本研究探讨D-004是否能改善大鼠口服睾酮后的PH值。将大鼠分为5组,每组10只。1组注射大豆油(阴性对照),4组注射睾酮:1组口服载药(阳性对照),2组口服D-004(200和400 mg/kg), 1组注射锯棕榈(400 mg/kg)。研究结束后,处死大鼠,取下前列腺并称重。与阳性对照相比,D-004(200和400 mg/kg)分别显著和剂量依赖性地减少了85%和98%的前列腺肥大。同样,与阳性对照组相比,锯棕榈(400 mg/kg)显著降低了73%的前列腺重量。D-004 (400 mg/kg)对前列腺肥大的抑制效果优于锯棕榈(400 mg/kg) (p < 0.05)。D-004和锯棕榈也降低了前列腺重量与体重比,但对体重没有影响。综上所述,口服D-004(200和400 mg/kg)可有效降低睾酮给药后的PH值。D-004 (400 mg/kg)比锯棕榈(400 mg/kg)更有效。但是,需要进一步的研究来证实目前的结果。
{"title":"Therapeutic effect of D-004, a lipid extract from Roystonea regia fruits, on prostate hyperplasia induced in rats.","authors":"D Carbajal,&nbsp;V Molina,&nbsp;R Mas,&nbsp;M L Arruzazabala","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Benign prostatic hyperplasia (BPH) is a nonmalignant growth of prostate leading to difficulty in urinating. Drug therapy, phytotherapy included, is frequently used to treat BPH. D-004 is a lipid extract from Roystonea regia fruits, and previous studies have shown that oral treatment with D-004 for 14 days prevented prostate hyperplasia (PH) induced by testosterone in rats. No information is available, however; about the effects of D-004 in reverting already established PH. This study investigated whether D-004 could improve PH after oral dosing with testosterone in rats. Rats were distributed in five groups (10 rats/group). One group was injected with soy oil (negative control) and four groups were injected with testosterone: one was orally treated with the vehicle (positive control), two with D-004 (200 and 400 mg/kg) and the other with Saw palmetto (400 mg/kg). At study completion, the rats were sacrificed and the prostates were removed and weighed. D-004 (200 and 400 mg/kg) significantly and dose-dependently decreased prostate enlargement by 85% and 98%, respectively, versus the positive control. Likewise, Saw palmetto (400 mg/kg) significantly reduced prostate weight by 73% versus the positive control. D-004 (400 mg/kg) was more effective (p < 0.05) than Saw palmetto (400 mg/kg) in lowering prostate enlargement. D-004 and Saw palmetto also decreased the prostate weight to body weight ratio, but did not affect body weight. In conclusion, D-004 (200 and 400 mg/kg) orally administered was effective for reducing PH after testosterone dosing. D-004 (400 mg/kg) was more effective than Saw palmetto (400 mg/kg). Further studies, however, are needed to corroborate the present results.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25811125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells. 微血管内皮细胞中晚期糖基化终产物(AGEs)对色素上皮衍生因子(PEDF)基因表达的抑制作用
S Yamagishi, T Matsui, H Inoue

Pigment epithelium-derived factor (PEDF) is a natural extracellular component of the retina with neuronal differentiating activity. Recently, decreased levels of PEDF in the mammalian eye have been shown to participate in the pathogenesis of diabetic retinopathy In addition, advanced glycation end products (AGEs), senescent macroprotein derivatives that form at an accelerated rate under diabetes, have also been implicated in the development and progression of diabetic retinopathy. However the role of AGEs in decreased levels of PEDF in the eye remains to be elucidated. In this study, we examined the effects of AGEs on PEDF gene expression in microvascular endothelial cells (ECs). Various types of immunochemically distinct AGEs, which were prepared in vitro by incubating bovine serum albumin with glucose, glyceraldehyde or glycolaldehyde, significantly decreased endothelial mRNA levels of PEDF Furthermore, H2O2 dose-dependently suppressed PEDF gene expression in ECs. Our present results suggest that AGEs could down-regulate mRNA levels of PEDF in ECs, probably via oxidative stress generation. The deleterious effects of AGEs on diabetic retinopathy could be due, at least in part, to their PEDF-inhibitory properties.

色素上皮衍生因子(PEDF)是一种天然的视网膜细胞外成分,具有神经元分化活性。最近,哺乳动物眼睛中PEDF水平的下降已被证明参与糖尿病视网膜病变的发病机制。此外,晚期糖基化终产物(AGEs),即糖尿病患者加速形成的衰老大蛋白衍生物,也与糖尿病视网膜病变的发生和进展有关。然而,AGEs在降低眼内PEDF水平中的作用仍有待阐明。在这项研究中,我们检测了AGEs对微血管内皮细胞(ECs)中PEDF基因表达的影响。在体外用葡萄糖、甘油醛或乙醇醛培养牛血清白蛋白制备不同类型的AGEs,可显著降低内皮细胞PEDF mRNA水平,H2O2剂量依赖性地抑制ECs中PEDF基因的表达。我们目前的研究结果表明,AGEs可能通过氧化应激产生下调ECs中PEDF的mRNA水平。AGEs对糖尿病视网膜病变的有害作用可能是由于,至少部分是由于它们的pedf抑制特性。
{"title":"Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells.","authors":"S Yamagishi,&nbsp;T Matsui,&nbsp;H Inoue","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Pigment epithelium-derived factor (PEDF) is a natural extracellular component of the retina with neuronal differentiating activity. Recently, decreased levels of PEDF in the mammalian eye have been shown to participate in the pathogenesis of diabetic retinopathy In addition, advanced glycation end products (AGEs), senescent macroprotein derivatives that form at an accelerated rate under diabetes, have also been implicated in the development and progression of diabetic retinopathy. However the role of AGEs in decreased levels of PEDF in the eye remains to be elucidated. In this study, we examined the effects of AGEs on PEDF gene expression in microvascular endothelial cells (ECs). Various types of immunochemically distinct AGEs, which were prepared in vitro by incubating bovine serum albumin with glucose, glyceraldehyde or glycolaldehyde, significantly decreased endothelial mRNA levels of PEDF Furthermore, H2O2 dose-dependently suppressed PEDF gene expression in ECs. Our present results suggest that AGEs could down-regulate mRNA levels of PEDF in ECs, probably via oxidative stress generation. The deleterious effects of AGEs on diabetic retinopathy could be due, at least in part, to their PEDF-inhibitory properties.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25812770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cefazolin concentrations in serum during cardiopulmonary bypass surgery. 体外循环手术期间血清头孢唑林浓度的变化。
P A Miglioli, F Merlo, G B Calabrò, F Allerberger, M Fille

The objective of the study was to investigate possible changes in cefazolin serum levels induced by cardiopulmonary bypass (CPB). Six cardiac male patients who underwent cardiac surgery requiring CPB took part in the study. Cefazolin 2 g was intravenously infused over 60 min before anesthesia and blood samples were taken at appropriate times after drug administration (0, 0.25, 0.5, 1, 4, 6, 8 h), 2 min before and 5 min after the beginning and 2 min before and 5 min after the end of CPB. Drug serum concentrations were determined by means of a microbiological method. Five minutes after the start of CPB, cefazolin serum levels decreased on average by 46.6% and remained steadily low until 5 min after the end of CPB. Then, they rose on average by 37.3% at 4 h and then declined slowly until the last sampling at 8 h. Cefazolin serum concentrations were low during CPB but remained in a potentially effective range for antimicrobial prophylaxis for this surgery.

本研究的目的是探讨体外循环(CPB)可能引起的头孢唑林血清水平的变化。6名接受心脏手术需要CPB的男性心脏病患者参加了这项研究。麻醉前60 min静脉滴注头孢唑林2g,给药后适当时间(0、0.25、0.5、1、4、6、8 h), CPB开始前2 min、开始后5 min, CPB结束前2 min、结束后5 min采血。用微生物法测定血清药物浓度。CPB开始后5分钟,头孢唑林血清水平平均下降46.6%,并稳定维持在低水平,直至CPB结束后5分钟。然后,它们在4小时平均上升37.3%,然后缓慢下降,直到8小时最后一次采样。头孢唑林血清浓度在CPB期间较低,但仍在该手术的抗菌预防的潜在有效范围内。
{"title":"Cefazolin concentrations in serum during cardiopulmonary bypass surgery.","authors":"P A Miglioli,&nbsp;F Merlo,&nbsp;G B Calabrò,&nbsp;F Allerberger,&nbsp;M Fille","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The objective of the study was to investigate possible changes in cefazolin serum levels induced by cardiopulmonary bypass (CPB). Six cardiac male patients who underwent cardiac surgery requiring CPB took part in the study. Cefazolin 2 g was intravenously infused over 60 min before anesthesia and blood samples were taken at appropriate times after drug administration (0, 0.25, 0.5, 1, 4, 6, 8 h), 2 min before and 5 min after the beginning and 2 min before and 5 min after the end of CPB. Drug serum concentrations were determined by means of a microbiological method. Five minutes after the start of CPB, cefazolin serum levels decreased on average by 46.6% and remained steadily low until 5 min after the end of CPB. Then, they rose on average by 37.3% at 4 h and then declined slowly until the last sampling at 8 h. Cefazolin serum concentrations were low during CPB but remained in a potentially effective range for antimicrobial prophylaxis for this surgery.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40935655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diet and Japanese herbal medicine for recalcitrant atopic dermatitis: efficacy and safety. 饮食与日本草药治疗顽固性特应性皮炎的疗效与安全性。
H Kobayashi, N Mizuno, H Teramae, H Kutsuna, S Ueoku, J Onoyama, K Yamanaka, N Fujita, M Ishii

We have been utilizing Kampo, a Japanese herbal medicine, together with lifestyle advice, for recalcitrant atopic dermatitis. To estimate the safety and efficacy of the treatment, we administered Kampo formulas to patients in whom conventional treatment failed to improve symptoms, along with dietary advice recommending traditional Japanese food. The therapeutic effects of Kampo formulas were assessed in 95 patients with recalcitrant atopic dermatitis who consulted our clinic from January to June, 2000. The overall result was 'markedly effective" in 19 patients (20%), "moderately effective" in 33 (35%), "slightly effective" in 36 (38%) and "ineffective" in four (4%). Three patients dropped out of the study. No adverse reactions in laboratory data were noted in examined patients. The most commonly used formula was Hochu-ekki-to containing Astragalus root, liquorice, jujube, ginseng, white Atractylodes rhizome, fresh ginger and Chinese Angelica root. Diet and Japanese herbal medicine are thought to be useful as an alternative therapy of intractable atopic dermatitis.

我们一直在使用Kampo,一种日本草药,连同生活方式的建议,顽固性特应性皮炎。为了评估治疗的安全性和有效性,我们对常规治疗未能改善症状的患者使用了汉布配方,并建议他们食用传统的日本食物。对2000年1 ~ 6月来我院就诊的95例难治性特应性皮炎患者进行了临床疗效评价。总体结果为:19例(20%)患者“显著有效”,33例(35%)患者“中等有效”,36例(38%)患者“轻微有效”,4例(4%)患者“无效”。三名患者退出了研究。检查的患者在实验室数据中未发现不良反应。最常用的配方是hochu - eksk -to,含黄芪、甘草、大枣、人参、白术、鲜姜和当归。饮食和日本草药被认为是一种有用的治疗顽固性特应性皮炎的替代疗法。
{"title":"Diet and Japanese herbal medicine for recalcitrant atopic dermatitis: efficacy and safety.","authors":"H Kobayashi,&nbsp;N Mizuno,&nbsp;H Teramae,&nbsp;H Kutsuna,&nbsp;S Ueoku,&nbsp;J Onoyama,&nbsp;K Yamanaka,&nbsp;N Fujita,&nbsp;M Ishii","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We have been utilizing Kampo, a Japanese herbal medicine, together with lifestyle advice, for recalcitrant atopic dermatitis. To estimate the safety and efficacy of the treatment, we administered Kampo formulas to patients in whom conventional treatment failed to improve symptoms, along with dietary advice recommending traditional Japanese food. The therapeutic effects of Kampo formulas were assessed in 95 patients with recalcitrant atopic dermatitis who consulted our clinic from January to June, 2000. The overall result was 'markedly effective\" in 19 patients (20%), \"moderately effective\" in 33 (35%), \"slightly effective\" in 36 (38%) and \"ineffective\" in four (4%). Three patients dropped out of the study. No adverse reactions in laboratory data were noted in examined patients. The most commonly used formula was Hochu-ekki-to containing Astragalus root, liquorice, jujube, ginseng, white Atractylodes rhizome, fresh ginger and Chinese Angelica root. Diet and Japanese herbal medicine are thought to be useful as an alternative therapy of intractable atopic dermatitis.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2004-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24948156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A two-year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction. 硫酸软骨素在手部糜烂性骨关节炎中的两年研究:糜烂、骨癣、疼痛和手部功能障碍的行为。
G Rovetta, P Monteforte, G Molfetta, V Balestra

The aim of this study was to evaluate the effect of 800 mg/die of chondroitin sulfate (CHS) per os plus naproxen versus naproxen over 2 years in patients with erosive osteoarthritis (EOA) of the hands. Joint count for erosions, Heberden and Bouchard nodes, Dreiser's algofunctional index and physicians' and patients' global assessment of disease activity were studied. A total of 24 consecutive patients (22 women and 2 men, mean age 53.0 +/- 6) suffering from symptomatic OA with radiographic characteristics of EOA were evaluated. The patients were divided into two groups of 12 patients each. The first group took naproxen 500 mg only. The second group was treated with CHS 800 mg orally plus naproxen 500 mg. Joint counts, radiological hand examinations and assessment of disease activity were performed at baseline, at 12 months and at 24 months. In the second year the treated group showed significant worsening in erosion, Heberden, Bouchard and Dreiser scores was recorded. Physician and patient global assessments of disease activity showed no significant difference from baseline scores. The untreated group showed significant worsening in erosion, Heberden and Bouchard nodes, Dreiser index and physician and patient global assessment scores. This study confirms the partial efficacy of oral CHS in improving some aspects of EOA.

本研究的目的是评估800毫克/例硫酸软骨素(CHS)加萘普生与2年萘普生对手部糜烂性骨关节炎(EOA)患者的影响。研究了糜烂关节计数、Heberden和Bouchard淋巴结、Dreiser's算法功能指数以及医生和患者对疾病活动性的整体评估。共有24例连续患者(22名女性和2名男性,平均年龄53.0±6岁)患有症状性OA,并评估其影像学特征。将患者分为两组,每组12例。第一组只服用萘普生500毫克。第二组患者口服CHS 800 mg +萘普生500 mg。在基线、12个月和24个月时进行关节计数、手部放射检查和疾病活动性评估。第二年,治疗组糜烂程度明显恶化,记录Heberden, Bouchard和Dreiser评分。医生和患者对疾病活动性的总体评估与基线评分没有显著差异。未治疗组糜烂、Heberden和Bouchard淋巴结、Dreiser指数和医患整体评估评分明显恶化。本研究证实了口服CHS在改善EOA某些方面的部分疗效。
{"title":"A two-year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction.","authors":"G Rovetta,&nbsp;P Monteforte,&nbsp;G Molfetta,&nbsp;V Balestra","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The aim of this study was to evaluate the effect of 800 mg/die of chondroitin sulfate (CHS) per os plus naproxen versus naproxen over 2 years in patients with erosive osteoarthritis (EOA) of the hands. Joint count for erosions, Heberden and Bouchard nodes, Dreiser's algofunctional index and physicians' and patients' global assessment of disease activity were studied. A total of 24 consecutive patients (22 women and 2 men, mean age 53.0 +/- 6) suffering from symptomatic OA with radiographic characteristics of EOA were evaluated. The patients were divided into two groups of 12 patients each. The first group took naproxen 500 mg only. The second group was treated with CHS 800 mg orally plus naproxen 500 mg. Joint counts, radiological hand examinations and assessment of disease activity were performed at baseline, at 12 months and at 24 months. In the second year the treated group showed significant worsening in erosion, Heberden, Bouchard and Dreiser scores was recorded. Physician and patient global assessments of disease activity showed no significant difference from baseline scores. The untreated group showed significant worsening in erosion, Heberden and Bouchard nodes, Dreiser index and physician and patient global assessment scores. This study confirms the partial efficacy of oral CHS in improving some aspects of EOA.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2004-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24510230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of angiotensin-converting enzyme inhibitor on collagenolytic enzyme activity in patients with acute myocardial infarction. 血管紧张素转换酶抑制剂对急性心肌梗死患者胶原溶解酶活性的影响。
D P Papadopoulos, E V Economou, T K Makris, K J Kapetanios, I Moyssakis, V E Votteas, P K Toutouzas

Matrix metalloproteinases and their tissue inhibitors are key enzymes degrading myocardial collagen in acute myocardial infarction (AMI). The aim of the present study was to determine whether angiotensin-converting enzyme inhibitors (ACEI) influence collagenase-1 (MMP-1) and their tissue inhibitor (TIMP-1) activity in AMI patients. Plasma levels of MMP-1, TIMP-1 and MMP-1/TIMP-1 complex were measured in 24 patients (aged 58.4 +/- 13.9 years) with AMI. Thirteen patients received perindopril 4 mg/day (group A) and 11 did not (group B). Plasma samples collected on admission and at 0, 3, 6, 9, 12, 18, 24, 36 and 48 hours and on days 3, 4, 5, 7, 15 and 30 thereafter were analyzed by relevant ELISA kits. Ejection fraction (EF) was assessed by ventriculography and end-diastolic diameter (EDD) echo-study on days 6 and 30. Values of collagenolytic enzymes of group A compared with those in group B were on average lower by 34%, 18.3% and 40%, respectively. The difference in values between groups at 0 h, 3 h and 9 h was significant (p < 0.048). ANOVA repeated measurement analysis showed significance within subjects for MMP-1 alone (p < 0.043) and for MMP-1 and ACEI (p < 0.046), while for TIMP-1 and MMP-1/TIMP-1 complex significance was only p < 0.0009. Regarding EDD changes, patients in group A showed minimal or no changes (51.23 +/- 1.8 mm to 51.6 +/- 2.13 mm), their EF was 38.8% and infarct size was medium to large. In contrast, group B showed a trend to increase EDD (41 +/- 0.78 mm to 42.33 +/- 0.59 mm), their EF was 50.5% and infarct size was small to medium. In conclusion, early initiation of ACEI treatment reduces collagenolytic activity. This effect may be considered an alternative mechanism for beneficial effects on postinfarction remodeling.

基质金属蛋白酶及其组织抑制剂是急性心肌梗死(AMI)中降解心肌胶原蛋白的关键酶。本研究的目的是确定血管紧张素转换酶抑制剂(ACEI)是否影响AMI患者的胶原酶-1 (MMP-1)及其组织抑制剂(TIMP-1)活性。测定24例AMI患者(年龄58.4±13.9岁)血浆MMP-1、TIMP-1及MMP-1/TIMP-1复合物水平。采用相应的ELISA试剂盒对入院时及入院后0、3、6、9、12、18、24、36、48 h及入院后第3、4、5、7、15、30天的血浆样本进行分析。在第6天和第30天分别通过心室造影和舒张末期内径超声检查评估射血分数(EF)。与B组相比,A组的胶原溶解酶值平均分别降低34%、18.3%和40%。0 h、3 h、9 h组间差异有统计学意义(p < 0.048)。方差分析重复测量分析显示,受试者间MMP-1单项差异显著(p < 0.043), MMP-1与ACEI单项差异显著(p < 0.046),而TIMP-1与MMP-1/TIMP-1复合差异显著(p < 0.0009)。在EDD变化方面,A组患者表现为微小或无变化(51.23 +/- 1.8 mm至51.6 +/- 2.13 mm), EF为38.8%,梗死面积为中~大。B组EDD呈增加趋势(41 +/- 0.78 mm ~ 42.33 +/- 0.59 mm), EF为50.5%,梗死面积小至中等。总之,早期开始ACEI治疗可降低胶原溶解活性。这种作用可能被认为是对梗死后重构有益作用的另一种机制。
{"title":"Effect of angiotensin-converting enzyme inhibitor on collagenolytic enzyme activity in patients with acute myocardial infarction.","authors":"D P Papadopoulos,&nbsp;E V Economou,&nbsp;T K Makris,&nbsp;K J Kapetanios,&nbsp;I Moyssakis,&nbsp;V E Votteas,&nbsp;P K Toutouzas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Matrix metalloproteinases and their tissue inhibitors are key enzymes degrading myocardial collagen in acute myocardial infarction (AMI). The aim of the present study was to determine whether angiotensin-converting enzyme inhibitors (ACEI) influence collagenase-1 (MMP-1) and their tissue inhibitor (TIMP-1) activity in AMI patients. Plasma levels of MMP-1, TIMP-1 and MMP-1/TIMP-1 complex were measured in 24 patients (aged 58.4 +/- 13.9 years) with AMI. Thirteen patients received perindopril 4 mg/day (group A) and 11 did not (group B). Plasma samples collected on admission and at 0, 3, 6, 9, 12, 18, 24, 36 and 48 hours and on days 3, 4, 5, 7, 15 and 30 thereafter were analyzed by relevant ELISA kits. Ejection fraction (EF) was assessed by ventriculography and end-diastolic diameter (EDD) echo-study on days 6 and 30. Values of collagenolytic enzymes of group A compared with those in group B were on average lower by 34%, 18.3% and 40%, respectively. The difference in values between groups at 0 h, 3 h and 9 h was significant (p < 0.048). ANOVA repeated measurement analysis showed significance within subjects for MMP-1 alone (p < 0.043) and for MMP-1 and ACEI (p < 0.046), while for TIMP-1 and MMP-1/TIMP-1 complex significance was only p < 0.0009. Regarding EDD changes, patients in group A showed minimal or no changes (51.23 +/- 1.8 mm to 51.6 +/- 2.13 mm), their EF was 38.8% and infarct size was medium to large. In contrast, group B showed a trend to increase EDD (41 +/- 0.78 mm to 42.33 +/- 0.59 mm), their EF was 50.5% and infarct size was small to medium. In conclusion, early initiation of ACEI treatment reduces collagenolytic activity. This effect may be considered an alternative mechanism for beneficial effects on postinfarction remodeling.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2004-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40866914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EPR evaluation of the antiradical activity of wines containing high concentrations of resveratrol. 含高浓度白藜芦醇葡萄酒抗自由基活性的EPR评价。
A Bertelli, M Falchi, R Lo Scalzo, R Morelli

The ability of two samples of red wine with different resveratrol concentrations to inhibit hydroxyl radicals (*OH) produced by a Fenton-type reaction was assessed using the method of electronic paramagnetic resonance (EPR). One sample was an autochthonous wine, Uvalino, which has a very high resveratrol concentration; the second was another red wine with a much lower resveratrol concentration. The ability of the sample of Uvalino wine to obstruct hydroxyl radicals was evident, but it wasn't much better than the ability of the sample of wine with a lower resveratrol concentration. The resveratrol concentration of wine is an important factor for the inhibition of the formation of free radicals, especially hydroxyl radicals; however, it is not the only one responsible for this property of wine. Resveratrol concentration can act synergically with other factors, such as polyphenols, which are also contained in wine and have antioxidant properties.

采用电子顺磁共振(EPR)方法研究了两种不同白藜芦醇浓度的红酒样品对fenton型反应产生的羟基自由基(*OH)的抑制能力。其中一个样本是当地出产的乌瓦利诺葡萄酒,它的白藜芦醇浓度非常高;第二种是另一种白藜芦醇含量低得多的红葡萄酒。乌瓦利诺(Uvalino)葡萄酒对羟基自由基的抑制作用明显,但并不比白藜芦醇浓度较低的葡萄酒强多少。葡萄酒中的白藜芦醇浓度是抑制自由基尤其是羟基自由基形成的重要因素;然而,它并不是葡萄酒这种特性的唯一原因。白藜芦醇浓度可以与其他因素协同作用,如葡萄酒中含有的具有抗氧化特性的多酚。
{"title":"EPR evaluation of the antiradical activity of wines containing high concentrations of resveratrol.","authors":"A Bertelli,&nbsp;M Falchi,&nbsp;R Lo Scalzo,&nbsp;R Morelli","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The ability of two samples of red wine with different resveratrol concentrations to inhibit hydroxyl radicals (*OH) produced by a Fenton-type reaction was assessed using the method of electronic paramagnetic resonance (EPR). One sample was an autochthonous wine, Uvalino, which has a very high resveratrol concentration; the second was another red wine with a much lower resveratrol concentration. The ability of the sample of Uvalino wine to obstruct hydroxyl radicals was evident, but it wasn't much better than the ability of the sample of wine with a lower resveratrol concentration. The resveratrol concentration of wine is an important factor for the inhibition of the formation of free radicals, especially hydroxyl radicals; however, it is not the only one responsible for this property of wine. Resveratrol concentration can act synergically with other factors, such as polyphenols, which are also contained in wine and have antioxidant properties.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2004-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24682059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Drugs under experimental and clinical research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1